Submit Manuscript  

Article Details


Inhibition of BACE, a Promising Approach to Alzheimers Disease Therapy

[ Vol. 2 , Issue. 4 ]

Author(s):

Silvio Roggo   Pages 359 - 370 ( 12 )

Abstract:


The first proteolytic step in the processing of amyloid precursor protein (APP) to amyloid-beta (Aβ) in the brain is performed by β-site APP cleaving enzyme (BACE1). This enzyme is a membrane bound aspartic protease with high homology of the catalytic domain to renin and pepsin and of yet unknown physiologic function. It is a primary drug discovery target for Alzheimers disease therapy. The first potent inhibitors are based on the sequence of APP around the β-secretase cleavage site EVNL / DAEF, with the scissile Leu-Asp amide bond being replaced by a hydroxyethylene transition state analogue isostere. In addition, lipophilic sidechains have been incorporated and a crystal structure of such an octapeptidic inhibitor bound in the active site is already available. Recent progress in the field of BACE inhibition is reviewed.

Keywords:

bace, aspartic protease, inhibition, app, amyliod, pepstatin, protease, indinavir, amprenavir, tipranavir, aliskiren

Affiliation:

Novartis Pharma AG, WSJ-507.605A, Lichtstrasse 35, CH-4056 Basel, Switzerland



Read Full-Text article